PE20050390A1 - Proceso para la elaboracion de telmisartan - Google Patents
Proceso para la elaboracion de telmisartanInfo
- Publication number
- PE20050390A1 PE20050390A1 PE2004000331A PE2004000331A PE20050390A1 PE 20050390 A1 PE20050390 A1 PE 20050390A1 PE 2004000331 A PE2004000331 A PE 2004000331A PE 2004000331 A PE2004000331 A PE 2004000331A PE 20050390 A1 PE20050390 A1 PE 20050390A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- biphenyl
- telmisartan
- compound
- acid
- Prior art date
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title abstract 6
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title abstract 3
- 229960005187 telmisartan Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- -1 SULFONYLOXY Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE TELMISARTAN QUE COMPRENDE LAS SIGUIENTES ETAPAS: (a) HACER REACCIONAR EL 2-N-PROPIL-4-METIL-6-(1´-METILBENCIMIDAZOL-2´-IL)-BENCIMIDAZOL CON UN COMPUESTO BIFENILO: 4-Z-METIL-2'-CIANO-BIFENILO), EN EL CUAL Z REPRESENTA UN GRUPO LABIL, PREFERENTEMENTE UN HALOGENO O SULFONILOXI SUSTITUIDO, SE LLEVA A CABO EN UN DISOLVENTE O EN UNA MEZCLA DE DISOLVENTES COMO CLORURO DE METILENO, DIETILETER, TETRAHIDROFURANO, DIMETILSULFOXIDO, ENTRE OTROS, EVENTUALMENTE EN PRESENCIA DE UN AGENTE LIGADOR DE ACIDOS, A UNA TEMPERATURA ENTRE 0 A 100°C Y EL COMPUESTO ASI OBTENIDO, EN CASO DESEADO, SE SOMETE A UNA ELABORACION; (b) EL GRUPO CIANO DEL COMPUESTO FORMADO: 2-CIANO-4´-[2´´-N-PROPIL-4´´-METIL-6´´-(1´´´-METILBENCIMIDAZOL-2´´´-IL)-BENCIMIDAZOL-1´´-IL-METIL] BIFENILO SE TRANSFORMA POR HIDROLISIS EN LA FUNCION ACIDO, EL CUAL SELLEVA A CABO EN AGUA, UN DISOLVENTE ORGANICO, O UNA MEZCLA DE ESTOS EN PRESENCIA DE UN ACIOD O BASE A TEMPERATURAS COMPRENDIDAS ENTRE 80 Y 200°C Y EL TELMISARTAN, ASI OBTENIDO, SE TRANSFORMA DURANTE LA ELABORACION, EN CASO DESEADO, EN EL HIDROCLORURO. TERMISARTAN ES UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA-II ADECUADO PARA EL TRATAMIENTO DE HIPERTENSION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10314702A DE10314702A1 (de) | 2003-03-31 | 2003-03-31 | Verfahren zur Herstellung von Telmisartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050390A1 true PE20050390A1 (es) | 2005-06-23 |
Family
ID=33016100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000331A PE20050390A1 (es) | 2003-03-31 | 2004-03-29 | Proceso para la elaboracion de telmisartan |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7193089B2 (es) |
| EP (2) | EP1611108B1 (es) |
| JP (1) | JP5160740B2 (es) |
| KR (1) | KR101096499B1 (es) |
| CN (1) | CN100418953C (es) |
| AR (2) | AR043794A1 (es) |
| AT (1) | ATE515500T1 (es) |
| AU (1) | AU2004226239B2 (es) |
| BR (1) | BRPI0408861A (es) |
| CA (1) | CA2520714C (es) |
| CL (1) | CL2004000687A1 (es) |
| CY (2) | CY1112020T1 (es) |
| DE (1) | DE10314702A1 (es) |
| DK (2) | DK2322511T3 (es) |
| ES (2) | ES2432647T3 (es) |
| IL (1) | IL171145A (es) |
| MX (1) | MXPA05009529A (es) |
| NZ (1) | NZ543244A (es) |
| PE (1) | PE20050390A1 (es) |
| PL (2) | PL2322511T3 (es) |
| PT (2) | PT1611108E (es) |
| RU (1) | RU2430092C2 (es) |
| SI (2) | SI2322511T1 (es) |
| TW (1) | TWI335916B (es) |
| UY (1) | UY28246A1 (es) |
| WO (1) | WO2004087676A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10314702A1 (de) * | 2003-03-31 | 2004-10-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von Telmisartan |
| GB2414019A (en) | 2004-05-11 | 2005-11-16 | Cipla Ltd | One-step preparation of telmisartan by condensation and hydrolysis |
| DE102004045796A1 (de) * | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
| EP1699765A1 (en) * | 2004-10-15 | 2006-09-13 | Teva Pharmaceutical Industries Ltd | Process for preparing telmisartan |
| WO2006044754A2 (en) | 2004-10-18 | 2006-04-27 | Dr. Reddy's Laboratories Ltd. | Process for preparing telmisartan |
| US7968727B2 (en) | 2005-04-01 | 2011-06-28 | Lek Pharmaceuticals, D.D. | Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists |
| ITMI20050801A1 (it) * | 2005-05-03 | 2006-11-04 | Dipharma Spa | Procedimento per la preparazione di telmisartan |
| WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
| US20060264491A1 (en) * | 2006-06-08 | 2006-11-23 | Chemagis Ltd. | Telmisartan production process |
| CN101172968B (zh) * | 2006-11-01 | 2010-05-12 | 浙江天宇药业有限公司 | 2-正丙基-4甲基-6-(甲基苯并咪唑-2-基)苯并咪唑盐及其制备方法 |
| CN101743228B (zh) * | 2007-07-03 | 2014-01-29 | 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 | 替米沙坦的制备方法 |
| CZ302272B6 (cs) | 2007-07-09 | 2011-01-19 | Zentiva, A. S. | Zpusob výroby 4´-[[4-methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-karboxylové kyseliny (telmisartanu) |
| WO2009116089A2 (en) * | 2008-03-14 | 2009-09-24 | Ipca Laboratories Limited | Novel intermediates and method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'- bi-1hbenzimidazol]-l-yl)methyl]-1,1-biphenyl]-2-carboxylic acid. |
| EP2103588A1 (en) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists |
| US8410285B2 (en) | 2008-03-20 | 2013-04-02 | Lek Pharmaceuticals D.D. | 2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists |
| EP2103609A1 (en) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | Catalyzed carbonylation in the synthesis of angiotensin ii antagonists |
| EP2123648A1 (en) | 2008-05-20 | 2009-11-25 | Chemo Ibérica, S.A. | A process for the preparation of Telmisartan. |
| EP2149566A1 (en) | 2008-07-15 | 2010-02-03 | Chemo Ibérica, S.A. | A process for the preparation of telmisartan |
| HRP20130557T1 (en) | 2009-06-19 | 2013-07-31 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
| EP2277866A1 (en) * | 2009-06-22 | 2011-01-26 | Inke, S.A. | Process for preparing telmisartan |
| EP2305650A1 (en) | 2009-09-21 | 2011-04-06 | Chemo Ibérica, S.A. | Novel process for the preparation of telmisartan |
| EA025946B1 (ru) | 2010-10-27 | 2017-02-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин |
| CN102267949A (zh) * | 2011-06-14 | 2011-12-07 | 张长利 | 替米沙坦制备新工艺 |
| WO2014027280A1 (en) | 2012-08-14 | 2014-02-20 | U Amarnath Amarnath | One pot process for the preparation of telmisartan |
| CN103787982A (zh) * | 2012-10-31 | 2014-05-14 | 上海特化医药科技有限公司 | 制备替米沙坦的方法及其中间体 |
| CN104557724B (zh) * | 2014-11-17 | 2017-01-11 | 江苏中邦制药有限公司 | 替米沙坦不定形晶型及其制备方法 |
| CN105130905B (zh) * | 2015-09-17 | 2017-09-08 | 浙江金立源药业有限公司 | 一种替米沙坦的合成方法 |
| CN109912512B (zh) * | 2017-12-13 | 2023-05-30 | 上海科胜药物研发有限公司 | 一种新的替米沙坦杂质化合物及其制备方法和用途 |
| CN112251770B (zh) * | 2020-10-14 | 2021-07-27 | 湖南大学 | 一种抗高血压药替米沙坦中间体电化学制备新方法 |
| CN113307775B (zh) * | 2021-04-16 | 2022-04-22 | 河北戴桥医药科技有限公司 | 一种替米沙坦的制备方法 |
| WO2023204729A1 (ru) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU1836357C (ru) * | 1990-07-23 | 1993-08-23 | Др.Карл Томэ ГмбХ | Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами |
| DE4023369A1 (de) * | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
| DE4103492A1 (de) * | 1991-02-06 | 1992-10-08 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE19901921C2 (de) * | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
| US6358986B1 (en) * | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
| US6737432B2 (en) * | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
| DE10314702A1 (de) * | 2003-03-31 | 2004-10-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von Telmisartan |
-
2003
- 2003-03-31 DE DE10314702A patent/DE10314702A1/de not_active Withdrawn
-
2004
- 2004-03-17 US US10/802,142 patent/US7193089B2/en not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408861-1A patent/BRPI0408861A/pt not_active Application Discontinuation
- 2004-03-26 EP EP04739071A patent/EP1611108B1/de not_active Expired - Lifetime
- 2004-03-26 MX MXPA05009529A patent/MXPA05009529A/es active IP Right Grant
- 2004-03-26 DK DK10192561.8T patent/DK2322511T3/da active
- 2004-03-26 NZ NZ543244A patent/NZ543244A/en not_active IP Right Cessation
- 2004-03-26 ES ES10192561T patent/ES2432647T3/es not_active Expired - Lifetime
- 2004-03-26 RU RU2005133479/04A patent/RU2430092C2/ru active
- 2004-03-26 SI SI200432083T patent/SI2322511T1/sl unknown
- 2004-03-26 ES ES04739071T patent/ES2369081T3/es not_active Expired - Lifetime
- 2004-03-26 PT PT04739071T patent/PT1611108E/pt unknown
- 2004-03-26 PL PL10192561T patent/PL2322511T3/pl unknown
- 2004-03-26 DK DK04739071.1T patent/DK1611108T3/da active
- 2004-03-26 AT AT04739071T patent/ATE515500T1/de active
- 2004-03-26 JP JP2005518684A patent/JP5160740B2/ja not_active Expired - Lifetime
- 2004-03-26 KR KR1020057018333A patent/KR101096499B1/ko not_active Expired - Lifetime
- 2004-03-26 AU AU2004226239A patent/AU2004226239B2/en not_active Expired
- 2004-03-26 EP EP10192561.8A patent/EP2322511B1/de not_active Expired - Lifetime
- 2004-03-26 SI SI200431740T patent/SI1611108T1/sl unknown
- 2004-03-26 CA CA2520714A patent/CA2520714C/en not_active Expired - Fee Related
- 2004-03-26 CN CNB2004800087194A patent/CN100418953C/zh not_active Expired - Lifetime
- 2004-03-26 PL PL04739071T patent/PL1611108T3/pl unknown
- 2004-03-26 WO PCT/EP2004/003217 patent/WO2004087676A1/de not_active Ceased
- 2004-03-26 PT PT101925618T patent/PT2322511E/pt unknown
- 2004-03-29 UY UY28246A patent/UY28246A1/es not_active Application Discontinuation
- 2004-03-29 TW TW093108537A patent/TWI335916B/zh not_active IP Right Cessation
- 2004-03-29 PE PE2004000331A patent/PE20050390A1/es not_active Application Discontinuation
- 2004-03-30 CL CL200400687A patent/CL2004000687A1/es unknown
- 2004-03-31 AR ARP040101066A patent/AR043794A1/es active IP Right Grant
-
2005
- 2005-09-28 IL IL171145A patent/IL171145A/en active IP Right Grant
-
2011
- 2011-09-28 CY CY20111100938T patent/CY1112020T1/el unknown
-
2012
- 2012-07-17 AR ARP120102582A patent/AR087209A2/es unknown
-
2013
- 2013-01-25 US US13/750,551 patent/US8993778B2/en active Active
- 2013-10-09 CY CY20131100879T patent/CY1115156T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050390A1 (es) | Proceso para la elaboracion de telmisartan | |
| PE20040781A1 (es) | Compuestos de purina como ligandos del receptor cannabinoide | |
| CL2009002097A1 (es) | Mezcla herbicida que contiene picolinafeno y por lo menos un compuesto herbicida seleccionado entre acidos quinolincarboxilicos, quinclorac o el quinmerac; agente herbicida que contiene la mezcla; procedimiento para preparar dicho agente herbicida. (divisional 523-04) | |
| ATE459352T1 (de) | Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe | |
| PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
| PE20091582A1 (es) | Procedimiento para la preparacion de dihidropteridinonas | |
| AR059977A1 (es) | Compuesto de ciclohexil piperidinil dihidrobenzimidazol composicion farmaceutica que lo comprende su uso para la preparacion de un medicamento proceso para preparalo y compuesto intermediario para la sintesis del mismo | |
| PE20060100A1 (es) | (orto-fenil)-anilidas de acido 1-metil-3-trifluorometil-pirazol-4-carboxilico como agentes fungicidas | |
| FR2865737B1 (fr) | Gel reticule biocompatible | |
| EA200702549A1 (ru) | Способ производства органического соединения | |
| ES2133610T5 (es) | Procedimiento para aumentar la proporcion de beta-modificacion en el polipropileno. | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| EP1746885A4 (en) | AGONISTS OF A2A ADENOSINE RECEPTORS FOR THE TREATMENT OF NEEDLE INJURY IN DIABETES | |
| CY1110443T1 (el) | Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων | |
| UY25971A1 (es) | Procedimiento de preparación de nuevos bencimidazoles, antagonistas de angiotensina ii. | |
| AR006439A1 (es) | Dihidrato de eprosartano y un procedimiento para su produccion y formulacion | |
| PE20070418A1 (es) | Procedimiento de preparacion para compuestos derivados de benzo[1,4]oxazin-3-ona | |
| EA200500005A1 (ru) | Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина | |
| PE20141549A1 (es) | VARIANTES DE CRIg MADURAS POR AFINIDAD | |
| ATE482931T1 (de) | Somatostatinrezeptor-1- und/oder -4-selektive agonisten und antagonisten | |
| DE60318716D1 (de) | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren | |
| CN204492700U (zh) | 油田修井作业机器人 | |
| PE20060740A1 (es) | Proceso de fabricacion de derivados de salicilamidas n-sustituidas | |
| CN105130905B (zh) | 一种替米沙坦的合成方法 | |
| DE602004013446D1 (de) | Quantitatives verfahren zum nachweis von yessotoxinen in fischprodukten auf grundlage der durch das toxin verursachten aktivierung zellulärer phosphodiesterase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |